Swiss Life Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Swiss Life Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,384	Closed	-$217K	–	1647
2026 Q1	$217K	Sell	5,384 -5,448	-50%	-$117K	﹤0.01%	1337
2025 Q4	$272K	Buy	+10,832	New	+$254K	﹤0.01%	1077

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Swiss Life Asset Management's APLS Position: Q2 2026 in Review

Swiss Life Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 5,384 shares — an estimated $217K sold.

Swiss Life Asset Management first reported a position in APLS in Q4 2025 and held it in 2 quarters. The position peaked at $272K in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Swiss Life Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Swiss Life Asset Management sold 5,384 Apellis Pharmaceuticals shares in Q2 2026, an estimated $217K.
Swiss Life Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Swiss Life Asset Management's Apellis Pharmaceuticals position peaked at $272K in Q4 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.